 |
인쇄하기
취소
|
Patients with kidney cancer to pay only 10% of Nexava NHI price.
Published: 2007-03-30 06:58:00
Updated: 2007-03-30 06:58:00
The NHI reimbursement of Nexava, a new oral anti-kidney cancer drug (sorafenib) and first in its kind in the world, has been approved by the MOHW. Now, the patient may pay only 10% of the drug charges under the NHI coverage. The NHI price for Nexava 200mg tablet is 25,486 won/T taking effects from April 1 this year.
Nexava was first approved by the U. S. FDA in Dec. 2005 for the treatment of k...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.